[Perspectives for drug treatment in Alzheimer's disease].
The last decade was very fruitful in neuropharmacology and notably in the therapeutic strategies of dementia and Alzheimer's disease (AD). The amount of data, information and breakthroughs is nevertheless difficult to apply in direct relationship with patients. The present review aims at classifying information according to their origins: epidemiology, clinical trials, neurosciences. A guide for drug prescription in Alzheimer's disease is thus warranted and becomes clearer, sure that, in the next future modifications and new strategies will appear. The main goal of the present review is to summarize the state-of-the-art for a non specialist in AD.
Allain
H
H
Laboratoire de Pharmacologie, Faculté de Médecine, Université de Rennes I, 2, avenue du Pr.-Léon-Bernard, CS 34317, 35043 Rennes Cedex, France. Herve.Allain@univ-rennes1.fr
Tribut
O
O
Reymann
J M
JM
Polard
E
E
Lecavorzin
P
P
Bentue-Ferrer
D
D
D000544:Alzheimer Disease / Q000188:drug therapy*; D002219:Carbamates / Q000008:administration & dosage; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use*; D000077265:Donepezil; D004359:Drug Therapy, Combination; D005702:Galantamine / Q000008:administration & dosage; D006801:Humans; D007189:Indans / Q000008:administration & dosage; D018697:Nootropic Agents / Q000627:therapeutic use; D048448:Phenylcarbamates; D010880:Piperidines / Q000008:administration & dosage; D000068836:Rivastigmine; D013619:Tacrine / Q000008:administration & dosage
D002219:Carbamates; D002800:Cholinesterase Inhibitors; D007189:Indans; D018697:Nootropic Agents; D048448:Phenylcarbamates; D010880:Piperidines; D005702:Galantamine; D013619:Tacrine; D000077265:Donepezil; D000068836:Rivastigmine
Perspectives médicamenteuses dans la maladie d'Alzheimer.